BACKGROUND: Triglyceride (TG) concentrations .2000 mg/dL are extremely elevated and increase the risk of pancreatitis.
Introduction
Severe hypertriglyceridemia is an uncommon disorder characterized by fasting plasma that is usually lipemic, with triglyceride (TG) concentrations . 885 mg/dL and an excess of TG-containing lipoprotein particles known as chylomicrons and very low-density lipoproteins (VLDL). 1 Chylomicrons are produced in the intestine in response to dietary fat, while VLDL is produced in the liver to export lipids, especially TG, into the bloodstream. 1 The classification of hyperlipoproteinemias published by Fredrickson, Levy, and Lees at the National Institutes of Health in 1967 associated severe hypertriglyceridemia with two types of hyperlipoproteinemias accordingly: type I, or chylomicronemia, and type V, or hyperprebetalipoproteinemia. 2 Patients with type I hyperlipoproteinemia had isolated chylomicron elevation on lipoprotein electrophoresis, whereas patients with type V hypertriglyceridemia had increases in both chylomicrons and VLDL. 2 Milky or lipemic plasma was first noted to be associated with eruptive xanthomas and with uncontrolled diabetes in 1921, and later cases without diabetes were described. 1 Subsequently, it was documented that such patients develop recurrent abdominal pain, which could be treated with a fatfree diet. 1 Havel and Gordon documented the deficiency of lipoprotein lipase (LPL) activity in these patients. 1 Thereafter, Brown et al at the National Institutes of Health showed that (1) the C apolipoproteins (apo) were important constituents of chylomicrons and VLDL, (2) apoC-II was the major activator of LPL, (3) apoC-III was the major inhibitor, modulating the catabolism of TG-rich lipoproteins, and (4) both LPL and hepatic lipase promoted postheparin lipolytic activity in plasma. [3] [4] [5] [6] [7] A study of 32 kindreds with primary type V hyperlipoproteinemia by Greenberg and Levy in 1977 documented linkage with diabetes, obesity, excess alcohol intake, and gout, but not premature coronary heart disease or abnormalities in postheparin lipolytic activity. 8 Breckenridge et al described a 59-year-old man with a long history of abdominal pain, marked hypertriglyceridemia, absent postheparin lipase activity, and a deficiency of apoC-II. 9 The patient's hypertriglyceridemia improved dramatically when he received a transfusion for anemia.
Since that time, significant increases in our understanding of the genetic causes of severe hypertriglyceridemia have occurred. The condition often results from homozygous or compound heterozygous mutations in the genes which encode LPL (LPL), its cofactors apoC-II (APOC2) and apoA-V (APOA5), the LPL chaperone lipase maturation factor 1 (LMF1), or glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1). 10 Patients with type I hyperlipoproteinemia generally present in childhood or adolescence with marked hypertriglyceridemia, very high levels of plasma chylomicrons, and often pancreatitis. Treatment of hypertriglyceridemia in a type I patient focuses on the restriction of dietary fat and control of secondary factors, as available pharmacological therapies, namely, fibrates and omega-3 fatty acids, are generally only minimally effective. 10 These patients generally have fasting TG levels . 2000 mg/dL and, in our view, should be characterized as having extreme hypertriglyceridemia.
Patients with type V hyperlipoproteinemia, also known as polygenic late-onset hypertriglyceridemia, generally have elevated plasma concentrations of both chylomicrons and VLDL. 2 This form of severe hypertriglyceridemia is approximately ten times more common than early-onset chylomicronemia. It is usually caused by an accumulation of several genetic variants, along with secondary factors such as uncontrolled diabetes, obesity, a poor diet, alcohol intake, and/or oral estrogens. 10 It also is associated with an increased risk of pancreatitis and may be associated as well with an increased risk of cardiovascular disease (CVD). 1 Polygenic late-onset hypertriglyceridemia is generally quite responsive to lifestyle modifications with diet (restriction of fat and sugar), exercise, weight loss, control of hyperglycemia, and therapy with fibrates and/or omega-3 fatty acids. 10 Our objective in this investigation was to report five cases of severe hypertriglyceridemia, which have been characterized at the molecular level, along with their clinical course and treatment response. Two of the patients had recurrent pancreatitis, one exacerbated by pregnancy. We also describe the efficacy of plasma exchange in controlling marked hypertriglyceridemia in one case that was successfully carried through two pregnancies with no subsequent episodes of pancreatitis and the delivery of three healthy offspring. The kindreds of two index cases were characterized. We aimed, in addition, to assess the prevalence of hypertriglyceridemia in a large reference population, using the European guideline cutpoints for fasting plasma TG levels, and to review the literature with regard to such cases. A European Atherosclerosis Society Consensus Panel has categorized hypertriglyceridemia as ''mild-to-moderate'' when fasting plasma TG concentrations are 177 to 885 mg/dL (2.0-10.0 mmol/L) and as ''severe'' when TG concentrations are . 885 mg/dL (.10 mmol/L). 11 However, many patients with these types of values do not develop pancreatitis and are often quite treatable with lifestyle modification, fibrates, and omega-3 fatty acid therapy. Patients with fasting plasma TG concentrations . 2000 mg/dL, who have been classified as having extreme hypertriglyceridemia, are much more likely to develop pancreatitis and are often much more difficult to treat. Therefore, we have added this category in our analyses.
Methods

Case reports
In all patients, plasma lipids were analyzed, after an overnight fast, for the measurement of total cholesterol, TG, and high-density lipoprotein cholesterol (HDL-C) using automated standardized assays as previously described. 12 Isolated DNA was sequenced at the APOA5, APOC2, LPL, GPIHBP1, and LMF1 gene loci by next-generation sequencing, at the London Regional Genomics Centre (London, ON, Canada) under the supervision of Dr Robert Hegele, as previously described. 13 Informatics analysis was performed by the same laboratory. Informed consent was obtained from all patients who underwent DNA sequencing.
Boston Heart Diagnostics reference population
The population studied in this analysis (440,240 subjects, 44.4% male) was selected from over a million blood samples sent by health care providers throughout the United States (by overnight express on cold packs) to Boston Heart Diagnostics over a 5-year period for the measurement of serum lipoproteins and plasma markers of glucose metabolism. Excluded from the study population were subjects sampled more than once (only data from the first sample were used) and those not sampled after an overnight fast. Information on the subjects with regard to gender, age, body mass index (BMI), diabetes, CVD, smoking, hypertension, and lipid-lowering medication was collected as reported by their health care providers. It should be noted that information on CVD, smoking, and hypertension status was often not provided. The number of subjects where data were provided is indicated in the table. The median age of this population, the gender percentage, and the lipid concentrations are quite similar to values previously obtained from subjects participating in cycle 6 of the Framingham Offspring Study. [14] [15] [16] However, because these subjects were not randomly selected, but were rather selected by their health care providers to have their serum and plasma biochemistries characterized by a reference laboratory, they may not be representative of middle-aged and elderly subjects in the general United States population. The population was divided by fasting TG concentration into 4 groups: ''normal,'' TG , 177 mg/dL (,2 mmol/L); ''moderate,'' TG 177 to 885 mg/dL (2-10 mmol/L); ''severe,'' TG 886 to 2000 mg/dL (.10-22.6 mmol/L); and ''extreme,'' TG . 2000 mg/dL (.22.6 mmol/L).
Fasting serum concentrations of total cholesterol, TG, HDL-C, direct low-density lipoprotein cholesterol (LDL-C), small dense LDL-C (sdLDL-C), apoA-I, apoB, glucose, insulin, glycated hemoglobin (HbA1c), and adiponectin were measured on automated COBAS analyzers (Roche Diagnostics, Indianapolis, IN), as previously described. 12, [14] [15] [16] All assays had within and between run coefficients of variation of , 5.0%. All assay kits were obtained from Roche Diagnostics, except for the sdLDL-C assay kit, which was obtained from the Denka Seiken Corporation (Tokyo, Japan). Non-HDL-C was calculated as the difference between total cholesterol and HDL-C; VLDL cholesterol (VLDL-C) as the difference between total cholesterol and the sum of LDL-C plus HDL-C. Values for the homeostasis model assessment of insulin resistance (HOMA-IR) were calculated based on levels of fasting glucose and fasting insulin as previously described. 17 
Statistical analysis
Statistical analyses on all population data were carried out using R Statistical Software (R Foundation for Statistical Computing, Vienna, Austria). Significant differences across TG categories were assessed using the nonparametric Kruskal-Wallis method with one-way analysis of variance for the numerical variables because many of these variables were not normally distributed, and the chi-squared test for trend in proportions for the categorical variables. A P value , .05 was considered statistically significant.
Results
Case 1
A 28-year-old female presented with a history of multiple episodes of severe pancreatitis beginning when she was 3 months of age. Her disease had been reasonably stable and well controlled on a strict low-fat diet, until her early twenties, when she again had recurrent attacks of pancreatitis resulting in at least 15 hospitalizations over a 4year period. She had had limited follow-up by a lipidologist, likely due to issues with health insurance. She had been treated with fenofibrate 160 mg/d, omega-3 fatty acid capsules 4 g/d, and niacin therapy, with limited TGlowering response. She was also on a strict low-fat diet and received medium-chain triglyceride (MCT) supplementation. The patient denied alcohol use but did admit to marijuana use to help with her abdominal pain.
At the initial clinic visit, the patient's physical examination was unremarkable. She was not jaundiced; and she did not have hepatomegaly, splenomegaly, xanthelasma, or eruptive xanthomas. Her fasting serum lipid concentrations were as follows: total cholesterol 114 mg/dL, TG 580 mg/dL, HDL-C 13 mg/dL, direct LDL-C 25 mg/dL, and VLDL-C 76 mg/dL (normal , 30 mg/dL). A negative urine pregnancy test and normal thyroid-stimulating hormone levels excluded pregnancy and hypothyroidism as causes of the patient's hypertriglyceridemia. Her liver and kidney function tests and electrolytes were within the normal range, but a complete blood count revealed modest leukocytosis and thrombocytosis, suggestive of inflammation. The patient had had several previously documented fasting serum TG concentrations . 2000 mg/dL, associated with bouts of pancreatitis and hospitalizations; and her serum lipase concentration of 2775 unit/L supported the diagnosis of acute pancreatitis.
A computed tomographic scan showed evidence of necrosis/fragmentation of the head of the pancreas, as well as a pancreatic pseudocyst ( Fig. 1 ). During hospitalizations, she usually received standard care for acute pancreatitis, consisting of intravenous fluids, nothing by mouth, which was followed by a strict low-fat diet and opiates for pain. This treatment in the past had resolved her acute symptoms and decreased her fasting TG levels to , 1000 mg/dL ( Fig. 2) .
During one of the subsequent admissions for acute pancreatitis, the patient was found to be 20 weeks pregnant. Her fasting serum TG concentration at that point was approximately 3500 mg/dL. With standard treatment as previously described, the patient improved. However, significant concerns over potentially life-threatening pancreatitis or central nervous system complications due to severe hypertriglyceridemia secondary to familial chylomicronemia with superimposed pregnancy were raised. A literature review revealed that the best treatment options were (1) long-term intravenous therapy with total parenteral nutrition to maintain caloric intake or (2) plasma exchange to remove TG-rich lipoproteins ( Fig. 3 ). [18] [19] [20] These options were discussed with the patient, as well as the risk of fetal or maternal demise if the hypertriglyceridemia was left untreated. The patient made an informed decision to proceed with weekly outpatient plasma exchanges.
Initially, as shown in Figure 2 , the patient's TG levels were in the 2000 mg/dL range before plasma exchange and , 1000 mg/dL after plasma exchange. However, during her third trimester, her pre-exchange TG levels increased to about 6000 mg/dL, and her plasma exchange sessions were increased to twice per week to control the hyperlipemia. With biweekly exchange sessions, her TG concentrations decreased dramatically, with postexchange TG levels being about 1000 mg/dL (Fig. 2 ). The patient had no subsequent episodes of pancreatitis and delivered a healthy male baby by spontaneous vaginal delivery at 36 weeks of gestation. When the plasma exchanges were discontinued six weeks after delivery, her TG concentrations were , 1000 mg/dL on a Before treatment Figure 2 Effect of triglyceride-lowering therapy on Case 1's fasting plasma triglyceride concentrations. The patient's severe hypertriglyceridemia and episodes of pancreatitis and hospitalizations were controlled before pregnancy with a strict low-fat diet and medium-chain triglyceride supplementation. During pregnancy and immediately after childbirth, she received weekly or biweekly plasma exchanges to remove the extremely lipemic filtrate. White bars depict before-treatment triglyceride levels; gray bars, after-treatment triglyceride levels. strict low-fat diet and MCT supplementation as before pregnancy. The patient chose not to breastfeed her child. The patient was later evaluated to participate in an investigational study for antisense APOC3 therapy (Akcea Therapeutics, Cambridge, MA). At the first study visit, she was found to be pregnant again, this time with twins. Her plasma TG levels during the second pregnancy were also managed with plasma exchanges (Fig. 2) .
DNA analysis revealed that the patient was a compound heterozygous for two pathogenic mutations in the LPL gene locus: a heterozygous c.708delA (p.G236Gfs*15) deletion and a heterozygous c.644G.A (p.G215E) missense mutation. Both mutations have previously been reported to impair LPL function. 21, 22 Case 1 kindred report
The proband's family history, presented in Figure 4 , was positive for severe hypertriglyceridemia and pancreatitis. Her father and brother had a history of marked hypertriglyceridemia, with her father having chronic pancreatitis but her brother reporting no episodes as a result; both were found to have the heterozygous LPL p.G236Gfs*15 deletion. Her mother was noted to have the heterozygous LPL p.G215E missense mutation. She had elevated TG levels, but no documented episodes of pancreatitis. One of the proband's two sisters had marked hypertriglyceridemia and also was a compound heterozygote for the LPL p.G236Gfs*15 deletion and the LPL p.G215E missense mutations. She had only one episode of pancreatitis during pregnancy in the past. The other sister had normal fasting TG concentrations and no mutations at the LPL, GPIHBP1, APOA5, APOC2, and LMF1 gene loci. The proband's first child had a TG concentration of 146 mg/dL and was found to be heterozygous for the LPL p.G215E missense mutation. The TG concentrations of her second and third children, fraternal twins, were 179 mg/dL (boy) and 176 mg/ dL (girl); and both were heterozygous for the LPL p.G236Gfs*15 deletion. These children all had TG concentrations well above the 90th percentile for males and females ages 0 to 4 years, which were 84 and 96 mg/dL, respectively.
Cases 2-4 and kindred report
Two female sisters (Cases 2 and 3), ages 6 weeks and 2 years, presented with lipemia and fasting TG . 1500 mg/ dL. Their parents were from the Middle East and were not known to be related. The 6-week-old infant was noted to have lipemia retinalis but had no signs or symptoms of pancreatitis. Her TG levels (after at least a 6-hour fast) fluctuated between 745 and 3150 mg/dL, despite discontinuing breast feeding and consuming a formula containing 50% of calories as fat and half of the fat as MCT oil. Her older sister had sparse eruptive xanthomas and intermittent mild abdominal pain but had no clear evidence of pancreatitis. She was counseled to follow a 15% to 20% fat diet supplemented with MCT oil, but her adherence was poor. Her fasting TG levels fluctuated between 750 and 1838 mg/dL. In both girls, DNA sequencing revealed a homozygous c.323C.G mutation in the GPIHBP1 gene causing a p.T108R amino acid substitution. The girls, currently 3 and 5 years of age, respectively, have never had severe abdominal pain or pancreatitis. On a very low- fat diet, their nonfasting plasma TG concentrations have ranged from 436 to 1838 mg/dL.
The mother of these children subsequently delivered twin boys who were both also noted to have severe hypertriglyceridemia, TG concentrations . 885 mg/dL, at a few days of age. They have grown well on Monogen, a modified fat formula, low in long-chain TG and high in MCT; and their nonfasting TG concentrations have varied between 401 and 622 mg/dL. No genetic analysis has been done to date. The mother herself reportedly had a normal fasting TG level. The father, however, had extremely elevated TG concentrations, which were first noted when he was 9 years of age, and had been intermittently treated with fibrates. At 26 years of age, he presented with a nonfasting TG concentration . 4400 mg/dL; after several days on an extremely low-fat diet, his fasting TG concentration was 1656 mg/dL. He denied having experienced any pancreatitis.
A first cousin of the father had a male child (Case 4) who presented with fasting TG concentrations . 25,000 mg/dL at one month of age and who was found to be homozygous for the same GPIHBP1 c.323C.G mutation found in Cases 2 and 3. While exclusively fed Monogen, his plasma TG concentrations fluctuated between 552 and 968 mg/dL; after table food was introduced, his nonfasting TG concentration was 1789 mg/dL. The boy is now 2-1/2 years of age and is growing normally. He has not had pancreatitis. The mother of this child was determined to be heterozygous for the GPIHBP1 c.323C.G mutation. The father was reported to have normal lipid levels but was not available for testing.
Therefore, in this extended kindred, as shown in Figure 5 , there are 3 known homozygotes for the GPIHBP1 c.323C.G mutation. It is likely that the father and infant twin brothers of Cases 2 and 3 are also homozygous, and that the mother is a heterozygote. Surprisingly in this kindred, no one has documented pancreatitis.
Case 5
A 43-year-old male presented with a history of three episodes of severe pancreatitis and hypertriglyceridemia (. 5000 mg/dL) in the prior 6 months. His BMI was 26.3 kg/m 2 , and his blood pressure was normal. His fasting serum sent to Boston Heart Diagnostics was found to be grossly lipemic, with a TG concentration . 5000 mg/dL, total cholesterol 298 mg/dL, HDL-C 15 mg/dL, direct LDL-C 11 mg/dL, VLDL-C 272 mg/dL, non-HDL-C 283 mg/dL, apoA-I 87 mg/dL, apoB 84 mg/dL, and lipoprotein (a) , 15 mg/dL. His apoE genotype was ε3/ε4. His fasting glucose concentration was 81 mg/dL; and his alkaline phosphatase, thyroid-stimulating hormone, blood urea nitrogen, creatinine, and electrolytes were all within normal limits.
The patient had no family history of pancreatitis or hypertriglyceridemia and reportedly had a normal fasting TG concentration , 177 mg/dL based on his medical records in the past. He also had no history of diabetes. He denied alcohol intake but did admit that his diet was not optimal. He was placed on a low-fat diet and received fenofibrate 145 mg/d, prescription fish oil (Lovaza, 4 g/d), and atorvastatin 40 mg/d; but his TG concentration remained elevated at 2526 mg/dL. Pioglitazone ? ? ? ? Figure 5 Cases 2-4 kindred with hypertriglyceridemia, no reported pancreatitis, and GPIHBP1 mutation. Squares and circles show genotype; arrow, proband; Roman numerals, the generations. HeGPIHBP1, heterozygous mutation in GPIHBP1; HoGPIHBP1, homozygous mutation in GPIHBP1; P, proband; TG, fasting triglyceride concentrations in mg/dL ( † nonfasting; ‡ treated); question mark, unanalyzed genotype. was noted most recently to have a fasting TG concentration of 73 mg/dL, a fasting glucose of 99 mg/dL, and a BMI of 28.5 kg/m 2 . DNA sequencing showed that the patient was a compound heterozygote, having a GPIHBP1 p.G175R amino acid substitution and an APOC2 intron 2-4G.C mutation. 23 Although these two variants are annotated as being of uncertain clinical significance, they have previously been associated with hypertriglyceridemia. 23 
Reference laboratory population data on hypertriglyceridemia
Data on a population of 440,240 subjects who had their samples sent to Boston Heart Diagnostics for specialized lipid analysis and other tests are shown in Table 1 . When divided by fasting plasma TG levels based on the 2014 European Atherosclerosis Society guidelines, 81.46% of the subjects had TG concentrations , 177 mg/dL (,2 mmol/L); 18.38% had TG concentrations in the 177 to 885 mg/dL (2-10 mmol/L) range; and 0.17% had TG concentrations . 885 mg/dL (.10 mmol/L). 11 When the group we have defined as having extreme hypertriglyceridemia (TG . 2000 mg/ dL) was added, 0.155% of the population had severe hypertriglyceridemia (885-2000 mg/dL) and 0.014% or 60 subjects had fasting TG concentrations . 2000 mg/dL ( Table 1 ). The percentage of men in each group increased significantly from the lowest to the highest TG group (42.1% to 80.0%), as did the percentage of subjects , 60 years of age (62.2% to 88.3%). As expected, the percentage of subjects with reported diabetes increased significantly (six-fold) across the TG groups, from 11.0% to 66.7%.
Median TG levels in each group also increased progressively, as expected, from 95 to 2382 mg/dL (25-fold overall increase). These increases were accompanied by marked increases in the median concentration of total cholesterol (1126%), non-HDL-C (three-fold), and VLDL-C (23-fold) in the extremely hypertriglyceridemic subjects versus the normal subjects, but only a 29% increase in apoB levels. Significantly lower levels of LDL-C (250%) and of sdLDL-C (213%) were noted in the extreme TG group compared to the normal group. As expected, HDL-C values were 45% lower in the extreme TG group, while apoA-I levels were 18% lower. With regard to biochemical markers of glucose homeostasis, fasting glucose concentrations were 89% higher, HbA1c values were 51% higher, insulin concentrations were two-fold higher, adiponectin concentrations were 63% lower, and HOMA-IR was more than three-fold higher in the extreme TG group compared to the normal TG group. The prevalence of hypertension and CVD was 75% and 56% higher (P , .0001), respectively, in the highest TG group than in the lowest TG group.
Discussion
Pedersen et al recently examined the relationship between nonfasting plasma TG concentrations and the risk of pancreatitis in 116,550 Danish subjects followed over a median of 6.7 years. Compared with individuals with plasma TG levels , 89 mg/dL, the multivariable adjusted hazard ratio (HR) and event rate per 10,000 person years for acute pancreatitis were: 1.6 and 4.3 events with TG concentrations of 89 to 176 mg/dL; 2.3 and 5.5 events with TG of 177 to 265 mg/dL; 2.9 and 6.3 events with TG of 266 to 353 mg/dL; 3.9 and 7.5 events with TG of 354 to 442 mg/dL; and 8.7 and 12 events with TG $ 443 mg/dL (P 5 6 ! 10 28 ). The multivariable adjusted HR for acute pancreatitis was 1.17 per 89 mg/dL higher TG concentration. When stratified by sex, age, education, smoking, hypertension, statin use, study cohort, diabetes, BMI, alcohol intake, and gallstone disease, these results were similar with no statistical evidence of interaction. Interestingly, in this same study, those with nonfasting TG concentrations . 443 mg/dL also had a 3.4-fold increased risk of CVD (78 events/10,000 person years) compared to those with nonfasting TG concentrations , 89 mg/dL. These data indicate that the risk of pancreatitis and CVD is significantly increased in subjects with nonfasting TG concentrations . 443 mg/dL and that there are about 6 times more CVD events than pancreatitis events. 24 Extrapolating these data to our extreme TG group would suggest a 25-fold increased risk of pancreatitis.
In another European study, the LPL, APOC2, APOA5, LMF1, and GPIHBP1 gene loci were sequenced in 413 subjects, 86 with type I and type V hyperlipoproteinemia and 327 controls. 25 In 46 (54%) of the hyperlipoproteinemic subjects, mutations were identified in the LPL (n 5 19), APOC2 (n 5 1), APOA5 (n 5 2), GPIHBP1 (n 5 3), and LMF1 (n 5 8) loci. In 22 (26%) subjects, only common variants in LPL (p.D36N, p.N318S, and p.S474X) and APOA5 (p.S19W) were identified. No mutations were found in 18 (21%) type I hyperlipoproteinemic subjects. The study revealed that the mutations in LMF1 were not associated with compromised LPL function, since five of the eight LMF1 variants were also found in the control subjects and, therefore, could not account for the observed phenotype. The investigators concluded that (1) the prevalence of mutations in LPL was 34%, mostly restricted to subjects with type I hyperlipoproteinemia; (2) mutations in GPIHBP1 (n 5 3), APOC2 (n 5 1) and APOA5 (n 5 2) were rare, but the associated clinical phenotypes were severe; and (3) sequencing of candidate genes in severe hypertriglyceridemia may help to guide future individualized therapeutic strategies in order to prevent pancreatitis.
Davidson et al recently evaluated the impact of familial chylomicronemia on the lives of 166 patients with a median age of 33 years and a median age at diagnosis of 9 years. 26 40% of the patients had been admitted to the hospital in the past year. Pancreatitis had occurred in 40%, with a lifetime mean of 13 episodes. Most patients (90%) found managing fat intake to be difficult, and 53% had experienced symptoms despite being on a strict diet. The disease had a significant impact on employment status, emotional/mental well-being, and social relationship. 26 The first comprehensive dietary guidelines for very low-fat diets in familial chylomicronemia have been presented by Williams et al. 27 These include a personal perspective on living with the disorder by one of the authors. Hegele et al carried out DNA sequencing in 52 patients with familial chylomicronemia, of whom 41 had biallelic LPL mutations, with mean fasting and four-hour postprandial TG levels of 2613 and 10,031 mg/dL, respectively. 28 In the remaining 11 patients, 2 had APOA5 mutations, 5 had GPIHBP1 mutations, 1 had an APOC2 mutation, and 1 had a LMF1 mutation.
In the present report, Case 1 was found to be a compound heterozygote for two pathogenic mutations in the LPL gene-a p.G236Gfs*15 deletion and a p.G215E missense mutation-and had severe hypertriglyceridemia and multiple episodes of pancreatitis. Both gene variants have previously been reported to impair LPL function; 21, 22 however, their impact in a kindred has not been addressed in the heterozygous state. Interestingly, the patient had one sister with the same mutations who also had hypertriglyceridemia but had only one episode of pancreatitis during pregnancy. Her father was a heterozygote for the deletion, and he had hypertriglyceridemia and multiple episodes of pancreatitis. However, her brother, with the same mutation as the father, had hypertriglyceridemia, but never had pancreatitis. Her mother was a heterozygote for the missense mutation and had hypertriglyceridemia, but never had pancreatitis. These data clearly indicate that subjects with the same genetic makeup can have profoundly different clinical outcomes. In addition, the data in this kindred suggest that the LPL deletion mutation is more likely to cause severe hypertriglyceridemia and pancreatitis than is the LPL missense mutation.
In the second kindred, there were three cases of severe hypertriglyceridemia documented to be due to a homozygous c.323C.G mutation in the GPIHBP1 gene causing a p.T108R amino acid substitution. These cases are clear examples of early-onset severe hypertriglyceridemia (fasting TG levels . 885 mg/dL). Interestingly, this mutation is located adjacent to a cysteine residue at position 110 and has previously only been reported once in the homozygous state, in a 1-year-old boy with a history of pancreatitis, but no TG data were provided. 25 Our kindred, in contrast, had no reported episodes of pancreatitis. It will be interesting to follow the homozygotes in this kindred and to extend it with further genetic analyses. They may be potential candidates for newer therapies for severe hypertriglyceridemia if they cannot be managed with standard therapy to prevent recurrent pancreatitis.
Most patients with severe hypertriglyceridemia (fasting TG . 885 mg/dL) can be easily managed by a diet restricted in fat and sugar, controlling their diabetes if present, and using fenofibrate, prescription omega-3 fatty acids, and if necessary statins, as well as in some cases metformin or pioglitazone. Case 5 is an example of how such patients can have a dramatic TG-lowering response. However, about 5% to 10% of such patients, usually without diabetes, do not respond to such regimens (such as Case 1). In these cases, the main (and preferred) therapeutic approach is a diet very low in fat (ideally , 20% of calories from fat) and MCT supplementation, which does not contribute to TG elevation. 10 Adherence issues, however, are common, particularly in younger patients. Very low-fat diets are often not very palatable. Patients must also thoroughly and continually watch the amount of fat they consume, an extremely challenging and difficult requirement for many, especially if they have an active social life or demanding school or work schedule. 26 Medications like fibrates, fish oil, and statins are often ineffective in lowering plasma TG concentrations, as was noted in Case 1. 10 Some success has been reported with either lomitapide or mipomersen drug therapy, currently only approved for homozygous familial hypercholesterolemia. 29, 30 Most recently, antisense inhibitors of apoC-III protein synthesis have been shown to be effective TG-lowering agents in patients with hypertriglyceridemia. 31 Pregnancy has long been known to exacerbate the situation in patients with early-onset severe hypertriglyceridemia. It has been documented that estrogen increases the production of TG-rich lipoproteins, which can aggravate hypertriglyceridemia in pregnancy. 32, 33 Strategies that have been reported to be successful in this circumstance include the use of total parenteral nutrition with intravenous omega-3 supplementation or plasmapheresis. [18] [19] [20] For Case 1, plasmapheresis was very effective in transiently lowering plasma TG levels, preventing pancreatitis in the mother, and promoting the successful delivery of three healthy children.
In their review of severe hypertriglyceridemia and pregnancy in 2012, Goldberg and Hegele reported on the case of a 26-year-old woman documented to have two LPL missense mutations (p.I194T and p.R243H) who presented at 3 weeks of age with failure to thrive and a TG value of about 11,000 mg/dL. 20 She was successfully treated with a low-fat diet (10% of calories from fat). During three pregnancies, she required periodic hospitalization for institution of a very strict low-fat diet and sometimes nothing by mouth and intravenous glucose solution. In addition, she was treated with gemfibrozil 300 mg orally twice daily during the third trimester and also received 1000 mg/d of omega-3 fatty acids during her third pregnancy. She had three normal offspring and never had pancreatitis in spite of the fact that her TG levels never got below 1700 mg/dL. These authors also reported on 8 additional cases between the ages of 20 and 35 years from the literature, all of whom were managed with low-fat diets, and in some cases with gemfibrozil 300 mg orally twice daily in the third trimester and omega-3 fatty acids 1 g/d, as well as with judicious hospitalization for a strict diet or nothing by mouth and intravenous fluids. None of these cases was documented to have mutations clearly associated with severe hypertriglyceridemia. One patient was treated with 13 plasma exchanges in her third trimester. All delivered normal children usually after induction or by Caesarean section. Only one case had intermittent low-grade pancreatitis during pregnancy but delivered a normal child; this case also had a history of pancreatitis during a prior pregnancy, which resulted in the intrauterine death of the fetus. 20 The authors comment that because the effects of therapeutic plasma exchange are transient, this option may not be optimum and efforts should be made to find other therapeutic options. We agree that other options should be sought. However, for our Case 1, there was no other viable option: plasma exchange was very effective and well tolerated, and the patient successfully delivered three healthy offspring.
Case 5 falls into the category of type V hyperlipoproteinemia and is more typical of the type of severe hypertriglyceridemia that many clinicians see in their practice. This patient presented with severe hypertriglyceridemia and pancreatitis at age 43 years with no prior history; he was found to have two genetic heterozygous variants, one in GPIHBP1 and one in APOC2. He was responsive to lifestyle modification, fibrates, omega-3 fatty acids, and statins. However, his plasma TG levels were not normalized until pioglitazone was added to his regimen despite the lack of diabetes, indicating the importance of improving insulin sensitivity in such patients, even those with normal fasting serum glucose levels. In these patients, it is also very important to control secondary causes of hypertriglyceridemia and to avoid medications which may worsen the hypertriglyceridemia, such as exogenous estrogens, corticosteroids, retinoids, b-blockers, thiazide diuretics, bile acid resins, antipsychotics, and antiretroviral agents. 10 Our reference laboratory population data clearly indicate that severe and extreme hypertriglyceridemia is more common in men and is strongly linked to diabetes. Severely hypertriglyceridemic patients often have low LDL-C levels but may still be at an increased risk of CVD because of the presence of insulin resistance and elevated levels of VLDL-C, as well as very low levels of HDL-C. Although TG concentrations . 2000 mg/dL are extremely uncommon in our population, with a prevalence of 0.01%, such patients, especially those with diabetes, are often encountered in lipid clinics, and generally respond very well to lifestyle modification, fibrates, and omega-3 fatty acids for TG-lowering. This was true for Case 5, although he was not normalized until a glucose-sensitizing agent was added to his regimen. The finding of a more than eight-fold increased risk of pancreatitis in those with nonfasting TG values . 443 mg/dL, compared to those with values , 89 mg/dL, in a large Danish population study, even after controlling for diabetes and gallstone disease, has important implications for pancreatitis prevention. 24 In conclusion, we agree with the current classification of hypertriglyceridemia as formulated by the European Atherosclerosis Society. 11 It may also be useful to add a category for extreme hypertriglyceridemia (TG . 2000 mg/dL). We favor characterization of the genetic defects in these cases to formulate therapy for the index case and provide prognostic information for family members. Removal of secondary causes, when present, is important. The use of more novel strategies, including plasma exchange in pregnancy, should be considered when other therapeutic modalities have failed. In addition to antisense therapy, gene therapy for patients with defined mutations will probably become available in the future.
